State of Israel
|
Not Applicable
|
(State or other jurisdiction of incorporation or organization)
|
(I.R.S. Employer Identification No.)
|
Kiryat Hadassah
Minrav Building – Fifth Floor
Jerusalem, Israel
(Address of Principal Executive Offices)
|
9112002
(Zip Code)
|
Large accelerated filer
|
☐
|
Accelerated filer
|
☐
|
|
Non-accelerated filer
|
☒
|
Smaller reporting company
|
☒
|
|
Emerging growth company
|
☐
|
Item 3. |
Incorporation of Documents by Reference.
|
(a) |
The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the Commission on March 8,
2024, pursuant to Section 13 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”);
|
(b) |
The Registrant’s Current Report on Form 8-K filed with the Commission on January 3, 2024; and
|
(c) |
The Registrant’s Registration Statement on Form 8-A filed with the Commission on June 25, 2018 (File No. 001-38556), in which there is
described the terms, rights and provisions applicable to the Ordinary Shares, including any amendment or report filed for the purpose of updating such description, including the description of the Ordinary Shares filed as Exhibit 4.1 to the Registrant’s Annual Report on Form 10-K filed on March 31, 2023.
|
Item 8. |
Exhibits.
The following are the exhibits required by Item 601 of Regulation S-K:
|
|
Exhibit No.
|
Description
|
|
|
ENTERA BIO LTD.
|
|
|
|
|
|
By:
Name:
Title:
|
/s/ Miranda Toledano
Miranda Toledano
Chief Executive Officer
|
Signature
|
Title
|
Date
|
||
/s/ Miranda Toledano
|
Chief Executive Officer and Director
(Principal Executive Officer)
|
March 8, 2024
|
||
Miranda Toledano
|
||||
/s/ Dana Yaacov-Garbeli
|
Chief Financial Officer
(Principal Financial and Accounting Officer)
|
March 8, 2024
|
||
Dana Yaacov-Garbeli
|
||||
/s/ Gerald Lieberman
|
Chairman of the Board
|
March 8, 2024
|
||
Gerald Lieberman
|
||||
/s/ Roger J. Garceau
|
Director
|
March 8, 2024
|
||
Roger J. Garceau
|
||||
/s/ Ron Mayron
|
Director
|
March 8, 2024
|
||
Ron Mayron
|
||||
/s/ Yonatan Malca
|
Director
|
March 8, 2024
|
||
Yonatan Malca
|
||||
/s/ Sean Ellis
|
Director
|
March 8, 2024
|
||
Sean Ellis
|
||||
/s/ Haya Taitel
|
Director
|
March 8, 2024
|
||
Haya Taitel
|
||||
/s/ Gerald M. Ostrov
|
Director
|
March 8, 2024
|
||
Gerald M. Ostrov
|
Yours faithfully,
|
|
/s/ Herzog Fox & Neeman Law Offices
|
|
Herzog Fox & Neeman Law Offices
|
We hereby consent to the incorporation by reference in this Registration Statement on Form S-8 of Entera Bio Ltd. of our report
dated March 8, 2024 relating to the financial statements, which appears in Entera Bio Ltd.'s Annual Report on Form 10-K for the year ended December 31, 2023.
/s/ Kesselman & Kesselman |
Certified Public Accountants (lsr.)
|
A member firm of PricewaterhouseCoopers International Limited
|
Tel-Aviv, Israel
|
March 8, 2024
|
Security Type
|
Security
Class Title |
Fee
Calculation Rule(2) |
Amount
Registered(1) |
Proposed
Maximum Offering Price Per Unit(2) |
Maximum
Aggregate Offering Price |
Fee Rate
|
Amount of
Registration Fee |
|||||||||||||||
Equity
|
Ordinary Shares, par value
NIS 0.0000769 per share, to be
issued under the Entera Bio Ltd.
2018 Equity Incentive Plan
|
Other
|
1,773,817(3)
|
|
$
|
1.42 |
$
|
2,518,820.14
|
|
$147.60 per
$1,000,000 |
$
|
371.78
|
|
|||||||||
Total Offering Amounts
|
$
|
2,518,820.14
|
|
$
|
371.78
|
|||||||||||||||||
Total Fee Offsets(4)
|
||||||||||||||||||||||
Net Fee Due
|
$
|
371.78
|
|
(1) |
Pursuant to Rule 416 of the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement shall also cover any additional ordinary shares, par value NIS 0.0000769 per share (“Ordinary shares”), of
Entera Bio Ltd. (the “Registrant”) that become issuable under the Entera Bio Ltd. 2018 Equity Incentive Plan (the “Plan”) by reason of any stock dividend, stock split, recapitalization or other similar transaction effected
without the receipt of consideration that results in an increase in the number of shares of the Registrant’s outstanding Ordinary Shares.
|
(2) |
Estimated solely for purposes of calculating the registration fee in accordance with Rules 457(c) and 457(h) of the Securities Act and based upon the average of the high and low sales prices of an Ordinary Share as reported on the Nasdaq
Capital Market on March 7, 2024.
|
(3) |
Represents an automatic annual increase of an aggregate of 1,773,817 Ordinary Shares pursuant to the increase on January 1, 2024 to the number of Ordinary Shares reserved for issuance under, and which annual increase is provided for in,
the Plan.
|
(4) |
The Registrant does not have any fee offsets.
|